Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2018-01-12 21:31:03
Reporting Period:
Accepted Time:
2018-01-12 21:31:03
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1264587 Stemline Therapeutics Inc STML Pharmaceutical Preparations (2834) 450522567
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1573722 Kenneth Hoberman C/o Stemline Therapeutics, Inc.
750 Lexington Avenue, Eleventh Floor
New York NY 10022
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-01-08 14,040 $13.93 384,792 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
  1. In connection with the vesting of 25,000 shares on January 8, 2018, a total of 14,040 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
  2. Reflects the weighted average sale price. The range of prices for such transaction is $13.70 to $14.05. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Of the 384,792 shares, 288,392 shares are restricted stock.